H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation ...

Fintel reports that on January 2, 2025, HC Wainwright & Co. initiated coverage of Corvus Pharmaceuticals (NasdaqGM:CRVS) with ...

Research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Corvus Pharmaceuticals in ...

Nukkleus Inc. NUKK gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company ...

Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical compan Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has earned a consensus recommendation of “Buy” from the four ...

H.C. Wainwright initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $11 price target Corvus is a clinical-stage ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals (CRVS – Research Report) ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...